PLC may potentially have anti-inflammatory qualities, which could benefit people with rheumatic diseases
Intended setting: Laboratory research use only
[4] Rubino, D.M., et al
A person with high-expression GIPR variants may achieve rapid satiety and fat loss with semaglutide alone, making carnitine unnecessary
None of BPC-157, TB-500, or GHK-Cu is FDA-approved as a drug, and BPC-157 in particular has been the subject of regulatory attention regarding compounding
Notably, the Hamilton Depression Rating Scale (HAMD-17) scores in this population correlate strongly with biomarkers of hepatic dysfunction (e.g., elevated gamma-glutamyl transferase) and neuronal injury (e.g., serum neurofilament light chain), suggesting a unique pathophysiology blending systemic and central nervous system (CNS) toxicity (Mirabdolhagh Hazaveh et al